Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 16S ribosomal RNA (rRNA) 3'-major domain is a primary structural component of the bacterial 30S ribosomal subunit, constituting the region known as the 'head' of the assembly (Wimberly et al., 2000, Nature). This domain is essential for the fidelity and efficiency of protein synthesis, as it coordinates the binding of messenger RNA (mRNA) and transfer RNAs (tRNAs) at the peptidyl (P) and exit (E) sites (Yusupov et al., 2001, Science). During the elongation phase of translation, the 3'-major domain undergoes significant conformational shifts, often described as 'head swiveling,' which are necessary for the translocation of the mRNA-tRNA complex (Ratje et al., 2010, Nature). Because this domain is highly conserved across bacterial species but distinct from eukaryotic rRNA, it is a potent target for antimicrobial therapy (Wilson, 2014, Nature Reviews Microbiology). Antibiotics like spectinomycin bind to helix 34 within this domain, physically blocking the swiveling motion and preventing translocation (Carter et al., 2000, Nature). Other inhibitors, such as kasugamycin, target the domain to interfere with the initiation of translation (Schluenzen et al., 2006, Nature Structural & Molecular Biology). Consequently, the 3'-major domain is a focal point for studying antibiotic mechanisms and the emergence of resistance mutations.
Inhibition of bacterial protein synthesis by binding to the 30S head and blocking translocation or initiation (Wilson, 2014, Nature Reviews Microbiology).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 16S ribosomal RNA 3'-major domain.